{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:51:43Z","timestamp":1791377503515,"version":"4.3.2"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009015","name":"Abbott Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Interv and Ther"],"DOI":"10.1007\/s12928-026-01348-1","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:54:53Z","timestamp":1791374093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose prasugrel versus clopidogrel for dual antiplatelet therapy after percutaneous coronary intervention: insights from the STOPDAPT-2 total cohort"],"prefix":"10.1007","author":[{"given":"Tsuyoshi","family":"Isawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Natsuaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Obayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanari","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruka","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Akao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-4076","authenticated-orcid":false,"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the STOPDAPT-2 and STOPDAPT-2 ACS Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"1348_CR1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","volume":"149","author":"M Natsuaki","year":"2024","unstructured":"Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, et al. an aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 Randomized Trial. Circulation. 2024;149:585\u2013600.","journal-title":"Circulation"},{"key":"1348_CR2","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa2507980","volume":"393","author":"PO Guimar\u00e3es","year":"2025","unstructured":"Guimar\u00e3es PO, Franken M, Tavares CAM, Antunes MO, Silveira FS, Andrade PB, et al. Early withdrawal of aspirin after PCI in acute coronary syndromes. N Engl J Med. 2025;393:2095\u2013106.","journal-title":"N Engl J Med"},{"key":"1348_CR3","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720\u2013826.","journal-title":"Eur Heart J"},{"key":"1348_CR4","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","volume":"85","author":"SV Rao","year":"2025","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the management of patients with acute coronary syndromes: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2025;85:2135\u2013237.","journal-title":"J Am Coll Cardiol"},{"key":"1348_CR5","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357.","journal-title":"N Engl J Med"},{"key":"1348_CR6","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315.","journal-title":"N Engl J Med"},{"key":"1348_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.5551\/jat.26013","volume":"22","author":"T Kimura","year":"2015","unstructured":"Kimura T, Isshiki T, Ogawa H, Yokoi H, Yamaguchi T, Ikeda Y. Randomized, double-blind, dose-finding, phase ii study of prasugrel in Japanese patients undergoing elective percutaneous coronary intervention. J Atheroscler Thromb. 2015;22:557\u201369.","journal-title":"J Atheroscler Thromb"},{"key":"1348_CR8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1253\/circj.CJ-19-1109","volume":"84","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, et al. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. Circ J. 2020;84:831\u201365.","journal-title":"Circ J"},{"key":"1348_CR9","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","volume":"78","author":"S Saito","year":"2014","unstructured":"Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome. Circ J. 2014;78:1684\u201392.","journal-title":"Circ J"},{"key":"1348_CR10","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1253\/circj.CJ-14-0266","volume":"78","author":"T Isshiki","year":"2014","unstructured":"Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, et al. Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary Intervention: Phase III, randomized, double-blind study. Circ J. 2014;78:2926\u201334.","journal-title":"Circ J"},{"key":"1348_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2004","volume":"3","author":"S Shoji","year":"2020","unstructured":"Shoji S, Sawano M, Sandhu AT, Heidenreich PA, Shiraishi Y, Ikemura N, et al. Ischemic and bleeding events among patients with acute coronary syndrome associated with low-dose prasugrel vs standard-dose clopidogrel treatment. JAMA Netw Open. 2020;3:e202004.","journal-title":"JAMA Netw Open"},{"key":"1348_CR12","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1253\/circj.CJ-24-0173","volume":"88","author":"T Kuno","year":"2024","unstructured":"Kuno T, Miyamoto Y, Akita K, Shoji S, Numasawa Y, Ueda I, et al. Low-dose prasugrel vs. standard-dose clopidogrel for patients undergoing percutaneous coronary intervention. Circ J. 2024;88:1745\u201353.","journal-title":"Circ J"},{"key":"1348_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.115.003519","volume":"9","author":"JA Valle","year":"2016","unstructured":"Valle JA, Shetterly S, Maddox TM, Ho PM, Bradley SM, Sandhu A, et al. Postdischarge bleeding after percutaneous coronary intervention and subsequent mortality and myocardial infarction: insights from the hmo research network-stent registry. Circ Cardiovasc Interv. 2016;9:e003519.","journal-title":"Circ Cardiovasc Interv"},{"key":"1348_CR14","doi-asserted-by":"publisher","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","volume":"17","author":"DJ Angiolillo","year":"2022","unstructured":"Angiolillo DJ, Galli M, Collet J-P, Kastrati A, O\u2019Donoghue ML. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention. 2022;17:e1371\u201396.","journal-title":"EuroIntervention"},{"key":"1348_CR15","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2019.8145","volume":"321","author":"H Watanabe","year":"2019","unstructured":"Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial. JAMA. 2019;321:2414\u201327.","journal-title":"JAMA"},{"key":"1348_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","volume":"7","author":"H Watanabe","year":"2022","unstructured":"Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the stopdapt-2 ACS randomized clinical trial. JAMA Cardiol. 2022;7:407\u201317.","journal-title":"JAMA Cardiol"},{"key":"1348_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.122.012004","volume":"15","author":"Y Obayashi","year":"2022","unstructured":"Obayashi Y, Watanabe H, Morimoto T, Yamamoto K, Natsuaki M, Domei T, et al. Clopidogrel monotherapy after 1-month dual antiplatelet therapy in percutaneous coronary intervention: from the STOPDAPT-2 total cohort. Circ Cardiovasc Interv. 2022;15:e012004.","journal-title":"Circ Cardiovasc Interv"},{"key":"1348_CR18","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344\u201351.","journal-title":"Circulation"},{"key":"1348_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.atherosclerosis.2007.12.006","volume":"200","author":"L Bax","year":"2008","unstructured":"Bax L, Algra A, Mali WPTM, Edlinger M, Beutler JJ, van der Graaf Y. Renal function as a risk indicator for cardiovascular events in 3216 patients with manifest arterial disease. Atherosclerosis. 2008;200:184\u201390.","journal-title":"Atherosclerosis"},{"key":"1348_CR20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/eurheartj\/ehv006","volume":"36","author":"H Reinecke","year":"2015","unstructured":"Reinecke H, Unrath M, Freisinger E, Bunzemeier H, Meyborg M, L\u00fcders F, et al. Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. Eur Heart J. 2015;36:932\u20138.","journal-title":"Eur Heart J"},{"key":"1348_CR21","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.jcin.2016.04.031","volume":"9","author":"T R\u00e5munddal","year":"2016","unstructured":"R\u00e5munddal T, Hoebers LP, Henriques JPS, Dworeck C, Anger\u00e5s O, Odenstedt J, et al. prognostic impact of chronic total occlusions: a report from scaar (swedish coronary angiography and angioplasty registry). JACC Cardiovasc Interv. 2016;9:1535\u201344.","journal-title":"JACC Cardiovasc Interv"},{"key":"1348_CR22","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2020.40","volume":"16","author":"JW Tan","year":"2021","unstructured":"Tan JW, Chew DP, Abdul Kader MASK, Ako J, Bahl VK, Chan M, et al. 2020 Asian pacific society of cardiology consensus recommendations on the use of p2y12 receptor antagonists in the asia-pacific region. Eur Cardiol. 2021;16:e02.","journal-title":"Eur Cardiol"}],"container-title":["Cardiovascular Intervention and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-026-01348-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12928-026-01348-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-026-01348-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:54:54Z","timestamp":1791374094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12928-026-01348-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":22,"alternative-id":["1348"],"URL":"https:\/\/doi.org\/10.1007\/s12928-026-01348-1","relation":{},"ISSN":["1868-4300","1868-4297"],"issn-type":[{"value":"1868-4300","type":"print"},{"value":"1868-4297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Watanabe reports personal fees from Abbott Medical Japan during the conduct of the study as well as personal fees from Abbott, AMGEN, Astellas, Daiichi-sankyo, Pfizer, Nipro, and Novartis outside the submitted work. Dr. Morimoto reports lecturer fees from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, GlaxoSmithKline, Integra LifeSciences, Pfizer, and UCB; advisory board for GlaxoSmithKline. Dr. Natsuaki reports honoraria from Abbott Medical Japan, Daiichi Sankyo, Medtronic, Terumo, Japan Lifeline, Asahi Intecc, Bristol-Myers Squibb, Otsuka, Amgen, Sanofi, Takeda and Bayer. Dr. Obayashi reports lecture fees from Abbott Medical Japan. Dr. Ando reports lecture fees from Abbott Medical Japan, Japan Life Line, Medtronic Japan, Biotronik Japan, and Novartis. Dr. Kimura reports grants from Abbott Medical Japan and Boston Scientific and being an advisory board member of Abbott Medical Japan and Terumo Japan.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In preparing this work, the authors utilized ChatGPT to enhance readability and language. Following this process, the authors carefully reviewed and edited the content as necessary and take full responsibility for the final publication.","order":2,"name":"Ethics","label":"Generative AI in scientific writing","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ShorT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent-2 [STOPDAPT-2]; NCT02619760, and ShorT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent-2 for the patients with ACS [STOPDAPT-2 ACS]; NCT03462498.","order":3,"name":"Ethics","label":"Clinical trial registration","group":{"name":"EthicsHeading","label":"Declarations"}}]}}